Golden Leaf Holdings Announces Completion of Debenture Payments

TORONTO, Aug. 23, 2019 (GLOBE NEWSWIRE) — Golden Leaf Holdings Ltd. (“Golden Leaf” or the “Company”) (CSE:GLH) (OTCQB:GLDFF), a pioneer cannabis oil solutions company and dispensary operator built around recognized brands, has announced the completion of the debenture payments.

On July 2, 2019, the Company issued 4,848,464 common shares at C$0.0782 to pay interest on the debentures for a total of C$379,150. 

On August 21, 2019, as disclosed, with greater than 98 percent support, the debenture holders approved the repayment of the principal amount of the convertible debentures of C$12,961,000 and accrued interest of C$190,815, via an early conversion today, August 23, 2019 at C$0.06. The Company issued 219,069,556 common shares to repay the principal and accrued interest. The original maturity date of these debentures was November 2, 2019.

In July 2019, the Company reached an agreement in principle to extend the due date for the $9,527,350 earn-out payment due to Chalice LLC and its members. This agreement was conditional on early settlement of the convertible debentures. As the debenture holders agreed to accelerate the settlement of the debentures, the agreement to extend the Chalice LLC earn-out payment from November 2, 2019 to May 2, 2022 became effective. The principal amount of the earn-out payment due to Chalice LLC and its members is $9,527,350, of which $5,000,000 is payable in cash and $4,527,350 is payable in the company’s common shares.

About Golden Leaf Holdings
Golden Leaf Holdings Ltd., a Canadian company with operations in multiple jurisdictions including Oregon, Nevada and Canada, is one of the largest cannabis oil and solution providers in North America, and a pioneer cannabis products company built around recognized brands. Golden Leaf cultivates, extracts, manufactures and distributes its products through its branded Chalice Farm retail dispensaries, as well as through third party dispensaries. Golden Leaf leverages a strong management team with cannabis and food industry experience to complement its expertise in extracting, refining and selling cannabis oil.  Visit goldenleafholdings.com to learn more.          

Company:
John Varghese
Interim CEO
Golden Leaf Holdings Ltd.
ir@goldenxtrx.com

Investor Relations:
Steve Hosein
Renmark Financial Communications
416-644-2020

Media Relations:
Anne Donohoe / Nick Opich
KCSA Strategic Communications
adonohoe@kcsa.com / nopich@kcsa.com
212-896-1265 / 212-896-1206

Disclaimer: This press release contains “forward-looking information” within the meaning of applicable securities legislation. Forward-looking information includes, but is not limited to, statements with respect to the Company’s future business operations, the opinions or beliefs of management and future business goals. Generally, forward looking information can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved”. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking information. These risks include but are not limited to general business, economic and competitive uncertainties, regulatory risks, market risks, risks inherent in manufacturing and retail operations such as unforeseen costs and production shutdowns, difficulties in maintaining brand loyalty, and other risks of the cannabis industry. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward looking information. Forward-looking information is provided herein for the purpose of presenting information about management’s current expectations relating to the future and readers are cautioned that such information may not be appropriate for other purpose. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws. This press release does not constitute an offer of securities for sale in the United States, and such securities may not be offered or sold in the United States absent registration or an exemption from registration or an exemption from registration.

Clinical data on Idorsia’s pipeline compounds will be presented at the European Society of Cardiology Congress 2019

Allschwil, Switzerland – August 23, 2019 

Idorsia Ltd (SIX: IDIA) today announced that data from Phase 2 studies with aprocitentan, a new dual endothelin receptor antagonist, and selatogrel, a highly-selective P2Y12 receptor antagonist, will be shared during the European Society of Cardiology (ESC) Congress 2019 in Paris, France.

Idorsia’s aprocitentan
An oral presentation entitled “Efficacy and safety of various doses of the new dual endothelin receptor antagonist aprocitentan in the treatment of hypertension“, will be part of the “Drug treatment in hypertension – New insights” session with a focused discussion with the lead author, Dr Parisa Danaietash from Idorsia, at 09:54 on August 31, 2019. The abstract can be found online.

Idorsia’s selatogrel
An oral presentation entitled “Selatogrel, a novel P2Y12 inhibitor for emergency use, achieves rapid, consistent and sustained platelet inhibition following single-dose subcutaneous administration in stable CAD patients“, will be part of the “New developments in anti-thrombotic drug therapy” session with a focused discussion with the lead author, Professor Robert Storey, BM, Professor of Cardiology, University of Sheffield, UK, at 17:15 on September 1, 2019. The abstract can be found online.

A second oral presentation entitled “Inhibition of platelet aggregation after subcutaneous administration of a single-dose of selatogrel, a novel P2Y12 antagonist, in acute myocardial infarction: A randomised open-label phase 2 study“, will be part of the “Emerging treatments in acute coronary syndromes” session with a focused discussion with the lead author, Professor Peter Sinnaeve, MD, Department of Cardiology, University Hospitals Leuven, Faculty of Medicine, University of Leuven, Belgium, at 11:34 on September 3, 2019. The abstract can be found online.

In addition, Idorsia representatives will be present at Stand B320 from 10:00 – 17:00 on Saturday, August 31, until Tuesday, September 3.

_______________

Notes to the editor

About aprocitentan
Aprocitentan is an orally active dual endothelin receptor antagonist, which is being investigated for patients whose hypertension is uncontrolled despite the use of three or more antihypertensive drugs.

In June 2018, Idorsia initiated PRECISION, a multi-center, double-blinded, placebo-controlled, randomized, parallel-group, Phase 3 study to demonstrate the antihypertensive effect of aprocitentan when added to standard of care in patients with resistant hypertension. Idorsia, in consultation with regulatory agencies, has designed a single study which will efficiently address both the short-term efficacy of aprocitentan and the durability of its effects in long-term treatment.

Patients with a history of resistant hypertension will undergo a thorough screening and run-in period. This will confirm the diagnosis of resistant hypertension by excluding pseudo or apparent resistant hypertension. During the screening period, the patient’s background antihypertensive therapies will be transitioned to a standardized fixed combination of a calcium channel blocker (amlodipine), an angiotensin receptor blocker (valsartan), and a diuretic (hydrochlorothiazide).

Patients with true resistant hypertension will then be randomized to receive aprocitentan 12.5 mg, 25 mg, or placebo once-daily. The study consists of 3 sequential treatment periods. The first is a double-bind treatment period designed to demonstrate the effect of aprocitentan on blood pressure at Week 4, compared to placebo. Patients then enter a treatment period where they are treated with aprocitentan 25 mg for 32 weeks. This is followed by a double-blind, randomized withdrawal treatment period where patients will remain either on aprocitentan 25 mg or switch to placebo for 12 weeks. The latter treatment period is designed to demonstrate the durability of the blood pressure lowering effect of aprocitentan. Patients will then enter a 30-day safety follow-up period.

From the initial screened patient population, at least 600 patients will be randomized and at least 300 patients are expected to complete the study. The study will be conducted in approximately 100 sites in around 20 countries.

In December 2017, Janssen Biotech, Inc. entered into a collaboration agreement with Idorsia to jointly develop and commercialize aprocitentan and any of its derivative compounds or products. Both parties have joint development rights over aprocitentan. Idorsia will oversee the Phase 3 development and regulatory submission. The costs will be shared equally between both partners. Janssen will oversee the Phase 3 development and submission for any additional indications.

Aprocitentan at ESC-19
Oral presentation:
Efficacy and safety of various doses of the new dual endothelin receptor antagonist aprocitentan in the treatment of hypertension.
Session: Drug treatment in hypertension – new insights, 34.
P Danaietash, P Verweij, B Flamion, J Menard, M Bellet; Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland, Clinical Investigation Centre, Inserm /Assistance Publique, Hôpitaux de Paris, Hôpital Européen and Université Paris-Descartes, Paris, France.
Saturday, August 31, 2019, 09:54 – 10:12

About selatogrel
Selatogrel is a highly-selective P2Y12 receptor antagonist developed for acute coronary syndrome.

Two Phase 2 studies in patients with stable coronary artery disease and acute myocardial infarction, respectively, have met their pharmacodynamic objectives of significantly inhibiting platelet aggregation. Subcutaneous administration of selatogrel 8 mg and 16 mg has demonstrated a rapid onset of action, within 15 minutes, with the height of its effect extending over 4-8 hours, depending on the dose. The predefined extent of platelet aggregation inhibition was seen in at least 89% of the patients in both chronic and acute situations across doses. Selatogrel was safe and well tolerated in both studies and there were no treatment-emergent serious bleeds. Idorsia is now preparing for the end of Phase 2 meetings with health authorities where it will discuss a Phase 3 study.

Selatogrel at ESC-19
Oral presentation:
Selatogrel, a novel P2Y12 inhibitor for emergency use, achieves rapid, consistent and sustained platelet inhibition following single-dose subcutaneous administration in stable CAD patients.
Session: New Developments in Anti Thrombotic Drug Therapy, 2349.
Robert Storey, Paul Gurbel, Stefan James, Jurrien ten Berg, Jean-Francois Tanguay, Corine Bernaud, Jean-Marie Frenoux, Abdel Hmissi, Mike Ufer, Pim Van der Harst, Arnoud Van’t Hof, George Dangas, Vijay Kunadian, Diana Gorog, Dietmar Trenk, Dominick Angiolillo.
Sunday, September 1, 2019, 17:15 – 17:32

Oral presentation:
Inhibition of platelet aggregation after subcutaneous administration of a single-dose of selatogrel, a novel P2Y12 antagonist, in acute myocardial infarction: A randomised open-label phase 2 study.
Session: Emerging Treatments in Acute Coronary Syndromes, 5232.
Peter Sinnaeve, Gregor Fahrni, Dan Schelfaut, Alessandro Spirito, Christian Mueller, Jean-Marie Frenoux, Abdel Hmissi, Corine Bernaud, Mike Ufer, Tizziano Mocetti, Shaul Atar, Marco Valgimigli.
Tuesday, September 3, 2019, 11:34 – 11:48

About Idorsia
Idorsia Ltd is reaching out for more – We have more ideas, we see more opportunities and we want to help more patients. In order to achieve this, we will develop Idorsia into one of Europe’s leading biopharmaceutical companies, with a strong scientific core.

Headquartered in Switzerland – a biotech-hub of Europe – Idorsia is specialized in the discovery and development of small molecules, to transform the horizon of therapeutic options. Idorsia has a broad portfolio of innovative drugs in the pipeline, an experienced team, a fully-functional research center, and a strong balance sheet – the ideal constellation to bringing R&D efforts to business success.

Idorsia was listed on the SIX Swiss Exchange (ticker symbol: IDIA) in June 2017 and has over 750 highly qualified specialists dedicated to realizing our ambitious targets.

For further information, please contact
Andrew C. Weiss
Senior Vice President, Head of Investor Relations & Corporate Communications
Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil
+41 (0) 58 844 10 10
www.idorsia.com

The above information contains certain “forward-looking statements”, relating to the company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “are expected to”, “will”, “will continue”, “should”, “would be”, “seeks”, “pending” or “anticipates” or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company’s investment and research and development programs and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company’s existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.

Attachment

Geocann is first-to-market introducing cannabigerol (CBG) formulations utilizing the VESIsorb® drug delivery system

CBG is among the many emerging cannabinoids and terpenes that Geocann is committed to pioneering through its technical formulation expertise and global distribution infrastructure.

FORT COLLINS, Colo., Aug. 23, 2019 (GLOBE NEWSWIRE) — Geocann is proud to announce that the company has successfully commercialized the first cannabigerol (CBG) soft gel products that utilize the multi-patented VESIsorb® delivery system for optimal absorption and measured bioavailability. The initial step is utilizing proprietary extraction technology to isolate and concentrate the CBG that allows Geocann to use its technical formulation expertise to address the active ingredient’s performance as it relates to dissolution, absorption, and bioavailability.

The first of two formulations is a combination of CBG and cannabidiol (CBD) while the second is a mono-CBG formulation. Both products include strategic inclusions of beta-caryophyllene (BCP) which has been shown to have synergistic effects as agonists for the CB2, 5-HT1A and glycine receptors.

“These product launches further advance Geocann’s leadership position as product development specialists that provide science-backed solutions to the industry’s formulation challenges,” said Marc Weder, Chief Scientific Officer. “The marketplace is demanding advancements beyond just CBD products and we are supremely positioned to deliver these solutions with more than three decades of research and product development expertise.”

Weder states that while the interest is high to include CBG (and other emerging cannabinoids and terpenes) in new formulations, the poor solubility and dissolution must be addressed to provide superior product solutions with the optimized absorption, bioavailability, and maximum therapeutic benefits consumers are seeking.

“Geocann has accomplished these results and has successfully transferred a rigorous product development protocol to the large-scale commercial production of soft gel capsules, topicals, foods, beverages, and sublinguals that combine these active ingredients with the VESIsorb® technology,” said Weder.

Geocann has worldwide exclusivity for cannabinoids formulated with VESIsorb®, and the company is quickly partnering with strategic brand leaders in key channels of distribution to deliver its robust portfolio of patent-protected products.

“The combination of CBD, CBG, and BCP powered by VESIsorb® in an elegant soft gel capsule is an important industry milestone,” said Jesse Lopez, CEO and founder. “Geocann will continue to pioneer the advancement of new cannabinoids, like CBG, CBN, and THCV, as it’s a privilege to offer these first-to-market opportunities to our brand partners.”

About Geocann
Geocann is a global cannabis organization led by experienced leadership with scientific and technical expertise for pioneering new innovations in natural health products and solutions. Its focus is combining clinically-researched cannabinoids with technologically-advanced and patented innovations that provide product differentiation with superior therapeutic performance and unmatched supporting evidence. For more information, please visit www.geocann.com.

About VESIsorb®
VESIsorb® is the leading delivery system innovation for dramatically improving the bioavailability of poorly absorbed ingredients, like cannabinoids. Since 2005, the advancement and superiority of this colloidal droplet delivery system have consistently been demonstrated in well-designed pilot and peer reviewed published pharmacokinetic absorption and bioavailability studies. For more information, please visit www.vesisorb.com.

For more information and interview requests, please contact Sam Davidson at 970-657-2479 or sam@geocann.com.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a46fa4f9-dbd3-4fb6-842d-40ecb895fee5

Cambium Networks to Present at the 2019 Deutsche Bank Technology Conference

ROLLING MEADOWS, Ill., Aug. 23, 2019 (GLOBE NEWSWIRE) — Cambium Networks Corporation (“Cambium Networks”) (NASDAQ: CMBM), a leading provider of wireless broadband networking infrastructure solutions, today announced that Atul Bhatnagar, president and CEO, will present at the Deutsche Bank Technology Conference in Las Vegas on Wednesday, September 11, 2019, at 8:00 a.m. PT/11:00 a.m. ET.

To join the live webcast, listeners should access the investor page of Cambium Networks website https://investors.cambiumnetworks.com/.  Following the live webcast, a replay will be available in the event archives at the same web address.

About Cambium Networks
Cambium Networks provides wireless broadband networking infrastructure solutions for network operators, including medium-sized wireless Internet service providers, enterprises and government agencies.  Cambium’s scalable, reliable and high-performance solutions create a purpose-built wireless fabric which connects people, places and things across distances ranging from two meters to more than 100 kilometers, indoors and outdoors, using licensed and unlicensed spectrum, at attractive economics. Headquartered outside Chicago and with R&D centers in the U.S., U.K. and India, Cambium Networks sells through a range of trusted global distributors.

Contacts: 
Investors:
Peter Schuman, IRC
Sr. Director Investor Relations
Cambium Networks
+1 (847) 264-2188
Peter.schuman@cambiumnetworks.com

Media:
Sara Black
Vice President
Bospar
+1 (213) 618-1501
sara@bospar.com

Arcoma inleder utvecklingsamarbete med Konica Minolta Europa

23 augusti 2019

PRESSRELEASE 

Arcoma inleder utvecklingsamarbete med  Konica Minolta Europa 

Arcoma har idag fått en order från Konica Minolta Europa på ett utvecklingsprojekt för två produkter baserade på Arcomas produktplattform och teknologi. Arcoma kommer att integrera Konica Minoltas detektorer och mjukvara för bildprocessning och bildhantering.  Målsättningen är att försäljning i Europa skall påbörjas under 2020 under Konica Minoltas varumärke. Parterna har också inlett förhandlingar om ett leverantörsavtal där Arcoma blir tillverkare av dessa produkter.  Förhandlingar om leverantörsavtalet är planerat att avslutas under hösten 2019 och leverans av produkter förväntas påbörja andra halvåret 2020. Denna order kommer inte att påverka Arcomas resultat under 2019.

”Konica Minolta utvecklar en komplett produktportfölj för diagnostisk röntgen genom samarbete med utvalda leverantörer. Syftet med detta project är att kombinera Konica Minoltas ”best-in-class” AeroDR detektorer med system av högsta kvalite för att kunna erbjuda unika och kostnadseffektiva lösningar till marknaden” säger Remy Bartels, General Manager OEM, Konica Minolta Business Solutions Europé, Healthcare Division.

“Vi är mycket nöjda och stolta över att Konica Minolta Europa har valt Arcoma som leverantör av sina mest avancerade röntgensystem. Vi ser fram emot ett produktivt samarbete där vi kommer att skapa kvalitetsprodukter och stödja Konica Minoltas lansering av dessa produkter under 2020. Denna typ av samarbete är enligt Arcomas strategi, att växa med partners, expandera produktportföljen och etablera nya säljkanaler” kommenterar Jesper Söderqvist, VD för Arcoma.

För ytterligare information, vänligen kontakta:

Arcomas VD,  Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soderqvist at arcoma.se

About Konica Minolta Europe Healthcare Division

Konica Minolta has been active in Healthcare for a long time. Starting out with Traditional X-Ray films based on Konica Minolta’s core competence in thin layer technology, the company has moved into digital X-Ray technology and has been active in this field since 2010 with it’s state of the art AeroDR product family. Konica Minolta’s Healthcare division in Europe is part of Konica Minolta Business Solutions Europe with headquarters in Langenhagen (Hannover, Germany), and Amsterdam, the Netherlands. Konica Minolta Europe is expanding it’s portfolio in X-ray and Healthcare-IT and has been growing its business by establishing successful cooperations with renowned partners all over Europe.

Om Arcoma

Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalitet och avancerad teknik. Arcomas produkter erbjuder den senaste digitala bildtekniken kombinerat med tekniskt avancerade rörliga positioneringssystem, vilket tillsammans med ergonomisk skandinavisk design, erbjuder kunden kompletta, konfigurerbara och funktionella digitala röntgensystem. Bolagets produkter säljs via återförsäljare samt via OEM-kunder och det finns idag över 3 500 av Arcomas röntgensystem installerade i hela världen. Arcoma är listat på Nasdaq First North.

Certified Adviser är Erik Penser Bank (tel: 08-4638300, e-mail: certifiedadviser@penser.se)

För mer information om bolaget besök www.arcoma.se

Denna information är sådan information som Arcoma AB är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning (MAR). Informationen lämnades, genom VD:s försorg, för offentliggörande den 23 augusti 2019 kl. 15.35

Attachment

JDRF Brings Together Aurora Community, Researcher, and Elected Officials to Discuss Affordable Access to Life-Changing Technologies for type 1 diabetes

AURORA, Ontario, Aug. 23, 2019 (GLOBE NEWSWIRE) — On Tuesday August 27, JDRF Canada will host a community forum to address the need for access to affordable type 1 diabetes (T1D) technologies for the more than 300,000 Canadians living with the disease who are otherwise burdened with crushing out-of-pocket costs that can amount to up to $15,000 every year per person.

Part of JDRF’s recently launched #AccessforAll campaign, the local ‘Technology and Diabetes: Access for All’ event provides an opportunity for residents to come together to discuss public coverage issues and to encourage adding advanced glucose monitor devices to public programs in Ontario.

What:   Technology and Diabetes: Access for All community forum
     
When:   Tuesday, August 27, 2019
    Media should please check-in at the registration desk located in the Magna Room
     
Time:   7:00pm to 8:30pm
     
Where:   Aurora Public Library, 15145 Yonge St., Aurora, ON
     
Who:   Dr. Nancy Tout, Head of Research & Development, Syngenta Canada;
    JDRF Ambassadors, Ann-Marie and Teagan Hulse;
    MP Leona Alleslev of Aurora — Oak Ridges — Richmond Hill;
    Mayor Tom Mrakas of Aurora;
    Mayor John Taylor of Newmarket;
    Coun. Sandra Humfryes;
    Coun. Wendy Gaertner;
    JDRF representative, Abidah Shamji, National Manager, Government Relations and Advocacy
     
Online:   jdrf.ca, jdrf.ca/accessforall, #AccessforAll, JDRF Canada Facebook, JDRF Canada Instagram
     

JDRF is the leading global organization funding type 1 diabetes research.

With an estimated 96,570 people living with type 1 diabetes in Ontario, a large number of Aurora residents are battling the following realities associated with T1D:

  • Every year about 1.4% of patients with type 1 diabetes are hospitalized due to hypoglycemia at a mean cost of C$3,775 per patient per year. Another 1.5% of type 1 diabetes patients end up with extra clinical appointments as a result of hypoglycemia at a mean cost of $157 per patient per year.
     
  • Parents, children and adults live with this everyday. Many parents and patients check blood glucose levels every 2 hours–even throughout the night– to prevent hospitalizations.
     
  • Patients with type 1 diabetes from a very young age and their families must manage their disease with insulin either through a pump or through injection. Even with this attention, patients may experience metabolic disorders, loss of consciousness or coma in the short term.
     
  • Over the long term, people with type 1 diabetes can experience serious complications, including stroke, heart disease, nerve damage, and eye damage, leading to blindness, amputations and death. Each complication is a significant burden to patients, their families and our health care system. New and innovative advanced glucose monitoring technologies, such as CGM and FGM are the standard of care in helping patients and families with type 1 diabetes to manage the disease, with great benefits to their quality of life. But with no public coverage for these devices, patients are left to cover the high costs out-of-pocket.
     
  • Type 1 diabetes is an autoimmune disease in which a person’s pancreas stops producing insulin, the hormone that enables people to get energy from food. This leads to higher levels of glucose in the blood and no amount of diet or exercise can prevent it.

For more information about the Technology and Diabetes: Access for All community forum and upcoming locations and dates, learn more about this pressing Canadian health issue, or to arrange interviews and/or photo opportunities please contact:

Soledad Vega
Marketing & Communications Manager at JDRF Canada
C: (647) 459-7881
svega@jdrf.ca

About JDRF Canada

JDRF is the leading global organization funding type 1 diabetes research. Our goal is to raise funds to support the most advanced international type 1 diabetes research and progressively remove the impact of this disease from people’s lives – until we achieve a world without type 1 diabetes. JDRF collaborates with a wide spectrum of partners and is the only organization with the scientific resources, regulatory influence, and a working plan to better treat, prevent, and eventually cure type 1 diabetes. JDRF is the largest charitable funder of and advocate for research to cure, prevent and treat T1D in the world. For more information, please visit jdrf.ca.

Zosano Pharma Announces Upcoming Oral and Poster Presentations at the Congress of the International Headache Society

  • Oral presentation of the safety and efficacy of QtryptaTM in a long-term safety study for the acute treatment of migraine.
  • Poster on the results of patients’ freedom from pain and most bothersome symptom when taking Qtrypta concurrently with prophylactic anti-CGRP antibodies.
  • Poster on the safety profile of Qtrypta when taken with serotonergic drugs.

FREMONT, Calif., Aug. 23, 2019 (GLOBE NEWSWIRE) — Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that the company will deliver an oral presentation and two poster presentations at the 19th Congress of the International Headache Society (IHC). The meeting will take place September 5-8, 2019 in Dublin, Ireland.

Oral Presentations Details  
Presentation Title: Long-term Safety of Qtrypta for the Acute Treatment of Migraine – 1-year Safety Results of Nearly 6,000 Treated Attacks
Presentation Date/Time: September 8, 2019 at 8:50 am IST
Presenter: Stephanie J. Nahas-Geiger, M.D., M.S.Ed., Thomas Jefferson University
Presentation Number: IHC-OR-043
   
Poster Presentations Details  
Poster Title: Efficacy of Qtrypta (zolmitriptan intracutaneous system) Before and After the Initiation of CGRP Antibody Therapy in Subjects with Migraine – a Preliminary Assessment
Presentation Date/Time: September 6, 2019 from 11:00 am to 12:00 pm IST
Presenter: Nada Hindiyeh, M.D., Stanford University
Poster Number: IHC-LB-025
   
Poster Title: Concomitant Use of Serotonergic Drugs with Zolmitriptan in a One-year Safety Trial
Presentation Date/Time: September 6, 2019 from 11:00 am to 12:00 pm IST
Presenter: Pete Schmidt, M.D., M.Sc., Zosano Pharma
Poster Number: IHC-LB-024

About Zosano Pharma
Zosano Pharma Corporation is a clinical stage biopharmaceutical company focused on developing products where rapid administration of established molecules with established safety and efficacy profiles may provide an increased benefit to patients, for markets where patients remain underserved by existing therapies. The company’s Adhesive Dermally-Applied Microarray (ADAM) technology consists of titanium microneedles coated with drug that is designed to enable rapid systemic administration of therapeutics to patients. Zosano’s lead product candidate is QtryptaTM (M207), which is an investigational, proprietary formulation of zolmitriptan delivered via ADAM technology, currently in development for the acute treatment of migraine. In February 2017, the company announced positive clinical and statistically significant results from the ZOTRIP pivotal study and in February 2019, the company announced the completion of the final milestone in its long-term safety study. The company is preparing to submit a New Drug Application to the Food and Drug Administration for Qtrypta (M207). Learn more at www.zosanopharma.com.

Forward-Looking Statements
This press release contains forward-looking statements regarding the expected data presentations for Qtrypta (M207) and other future events and expectations. Readers are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “might,” “believes,” “estimates,” “projects,” “potential,” “expects,” “plans,” “anticipates,” “intends,” “continues,” “forecast,” “designed,” “goal,” “unaudited,” “approximately” or the negative of those words or other comparable words to be uncertain and forward-looking. These statements are subject to risks and uncertainties that are difficult to predict, and actual outcomes may differ materially. These include risks and uncertainties, without limitation, associated with the process of discovering, developing and commercializing products that are safe and effective for use as human therapeutics, risks inherent in the effort to build a business around such products and other risks and uncertainties described under the heading “Risk Factors” in the Company’s most recent quarterly report on Form 10-Q. Although Zosano believes that the expectations reflected in these forward-looking statements are reasonable, we cannot in any way guarantee that the future results, level of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. All forward-looking statements are based on information currently available to Zosano and Zosano assumes no obligation to update any such forward-looking statements.

Zosano Contact:
Greg Kitchener
Chief Financial Officer
510-745-1200

PR Contacts:
Sylvia Wheeler or Alexandra Santos
swheeler@wheelhouselsa.com or asantos@wheelhouselsa.com

Bravo Recognized as a 2019 NorthCoast 99 Award Winner

CLEVELAND, Aug. 23, 2019 (GLOBE NEWSWIRE) — Bravo is honored to be recognized by ERC as a 2019 NorthCoast 99 Award recipient. This is the first year the organization has been named among the 99 great workplaces for top talent in Northeast Ohio.

NorthCoast 99 winners participated in a rigorous application process that asked for detailed information on how their organization attracts top-performers and invests in their development in five distinct areas: organizational strategy, policies, and communication; recruitment, selecting, and onboarding; employee well-being; employee engagement and development; and total rewards.

“After ten years in business, we are even more dedicated to strengthening and improving the processes to empower our employees. The NorthCoast 99 award is validation that we’re continuing to take steps in the right direction to attract and retain top talent in Northeast Ohio,” said Shannon Ross, Vice President of Human Resources at Bravo. “We have a responsibility as leaders to continuously improve our culture on behalf of our employees.”

Bravo has intentionally built initiatives that focus on the experience for candidates, new hires and employees. In 2018, several programs were developed and launched including new hire welcome kits, an eLearning platform for career development and employee recognition for those living out the company’s core values.

“With the recent collaboration with Cleveland Clinic, our continued growth of product offerings, and the addition of over ten positions in the last quarter, Bravo is poised for another decade of growth and looking to expand its top talent,” added Jim Pshock, Bravo’s founder and CEO. “We have a lot to look forward to, and I am honored that ERC has recognized the value we place on our employees.”

For a list of current job opportunities at Bravo, please visit https://www.bravowell.com/about-bravo-wellness/careers-at-bravo-wellness.

About Bravo

Founded in 2008, Bravo is a national provider of employee well-being solutions that empower employers and health plans with configurable wellness programs that strengthen employee benefits and drive down the long-term claims trend. Their data-driven approach has established proven models for controlling rising healthcare costs, inspiring personal improvement and attracting/retaining top talent. For more information, visit www.bravowell.com.

About ERC

Founded in 1920, ERC helps organizations make their workplaces great by providing expert people solutions that include training, consulting, research, and HR support services. ERC also sponsors the ERChealth insurance program in Ohio. Additional information about ERC and its services can be found at www.yourERC.com.

CONTACT: For more information, please contact:
Bravo Marketing at 877.662.7286

Seelos Therapeutics Announces Pricing of $6.7 Million Registered Direct Offering

NEW YORK, Aug. 23, 2019 (GLOBE NEWSWIRE) — Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, announced today that it has entered into a securities purchase agreement with certain institutional investors, providing for the purchase and sale of 4,475,000 shares of common stock at a price of $1.50 per share in a registered direct offering, resulting in total gross proceeds of approximately $6.7 million, before deducting the placement agents’ fees and other estimated offering expenses. The Company also agreed to issue to the investors unregistered warrants to purchase up to 2,237,500 shares of common stock in a concurrent private placement. The warrants have an exercise price of $1.78 per share of common stock, will be exercisable six months from the date of issuance and will expire four years following the date of issuance.

The registered direct offering and concurrent private placement are expected to close on or about August 27, 2019, subject to the satisfaction of customary closing conditions.

Seelos currently intends to use the net proceeds from the offering for general corporate purposes and to advance the development of its product candidates.

Roth Capital Partners is acting as the sole placement agent for the offering.

In connection with the registered direct offering and concurrent private placement, the Company required each investor to enter into a leak-out agreement until September 20, 2019. After giving effect to the leak-out agreements, each such investor is limited to a specified percentage of the trading volume on each trading day during the restricted period. The maximum percentage of the trading volume that an investor may sell is its pro rata portion of 35%. Sales of common stock over $3.00 per share will be excluded from the leak-out restrictions.

A shelf registration statement on Form S-3 (File No. 333-221285) relating to the shares of common stock to be issued in the registered direct offering was previously filed with the Securities and Exchange Commission (the “SEC”) on November 2, 2017, amended on December 1, 2017 and declared effective by the SEC on December 7, 2017. Such shares are being offered only by means of a prospectus. A prospectus supplement and the accompanying prospectus relating to and describing the terms of the registered direct offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. When available, copies of the prospectus supplement and the accompanying prospectus relating to the registered direct offering may also be obtained by contacting Roth Capital Partners, LLC, 888 San Clemente Drive, Newport Beach, California 92660, by calling (800) 678-9147 or by e-mail at rothecm@roth.com.

The unregistered warrants described above were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Act”), and Regulation D promulgated thereunder and, along with the shares of common stock underlying the warrants, have not been registered under the Act or applicable state securities laws. Accordingly, the warrants and underlying shares of common stock may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Act and such applicable state securities laws.

This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About Seelos Therapeutics:

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare disorders. The Company’s robust portfolio includes several late-stage clinical assets targeting psychiatric and movement disorders, including orphan diseases. Seelos is based in New York, New York. For more information, please visit our website: http://seelostherapeutics.com, the content of which is not incorporated herein by reference.

Forward-looking Statements:

This press release contains forward-looking statements related to Seelos Therapeutics, Inc. and its subsidiaries under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements regarding Seelos’ expectations on the timing and completion of the financing and the anticipated use of proceeds therefrom and other matters that are described in Seelos’ most recent periodic reports filed with the Securities and Exchange Commission, including Seelos’ Annual Report on Form 10-K for the year ended December 31, 2018, subsequent Quarterly Reports on Form 10-Q and the prospectus supplement related to the registered direct offering filed with the Securities and Exchange Commission on or about the date hereof, including risks and uncertainties associated with general economic and market conditions and the satisfaction of customary closing conditions and the other risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release and Seelos disclaims any intent or obligation to update these forward-looking statements except as required by law.

Contact Information:
Anthony Marciano
Head of Corporate Communications
Seelos Therapeutics, Inc. (Nasdaq: SEEL)
300 Park Ave., 12th Fl
New York, NY 10022
(646) 293-2136
anthony.marciano@seelostx.com
www.seelostherapeutics.com
https://twitter.com/seelostx
https://www.linkedin.com/company/seelos 

Rafarma to Commence Production in Thailand; Predicted to Be The Region’s “Cannabis Capital”

Ljubljana, Slovenia, Aug. 23, 2019 (GLOBE NEWSWIRE) — RAFARMA PHARMACEUTICALS INC. “OTC:(RAFA) – Rafarma is positioning to expand its operations in the “next big thing” in cannabis production—Thailand.

Rafarma is currently in talks with Thai partners to open cannabis farms and specialized cannabis spa and detox centers in Thailand. Projected plans are to construct hemp growing greenhouses as well as a specialized spa/detox center with full-control patient living facilities the following year on approximately 1000 rai (160 hectares) in the Ranong province of Thailand.

“The forecast for the legal cannabis market in Asia is rosy—it’s expected to swell to $8.5 billion by 2024 from practically nothing today. One of the main questions surrounding this potential market is which country will establish an early lead as a supplier. Surprisingly, Thailand has a good shot” according to Bloomberg Businessweek (https://www.bloomberg.com/news/articles/2019-07-18/thailand-is-poised-to-take-an-early-lead-in-the-cannabis-race?fbclid=IwAR3fOOtTNK1-haU3dGgUyEspc3rD1QPZX99Ddvru1VaflVDcIRhzs287M_Y)

Despite its history of tough drug laws, Thailand is looking to become the region’s cannabis capital. On February 20, 2019 Thailand passed an amendment to its current drug laws legalizing marijuana production for agricultural, commercial, medical and industrial purposes. The Bloomberg article goes on to report that in addition to changes in the laws, a key member of the current government coalition is pushing for full legalization of Thailand’s marijuana market, projected to grow to $661 million within five years, according to cannabis industry researchers.

Based on the legal changes, the Thailand Ministry of Health has undertaken several steps allowing storage of cannabis for medical and research purposes. Also, possession of cannabis is allowed for government organizations, private universities, private enterprises, farms, and for international logistics carriers and patients. Thailand is currently one of the first countries in the world that is expected to further relax laws to allow recreational cannabis use in the near future. 

Already, under current laws, scientists that practice traditional Thai medicine (the Spa Industry), as well as doctors, the Red Cross and farms that receive the permission from the government, are allowed to store and sell cannabis. The Thailand Ministry of Health officially recognized the properties of cannabis for wound healing, pain analgesia, after-illness or surgery rehabilitation, expectoration, cholagogue, anti-cancer, anti-stress, anti-depression and anti-insomnia.

As Thailand already offers the opportunity of combining the production of cannabis with its use and sales in unique specialized SPA centers and detox centers, and as such applications fully comply with current legislation, Rafarma is poised to meet the demand.

Forward-Looking Statements: This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934. Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate,” or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risk, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in the Company’s filings with OTC Markets. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

For more information contact:

RAFARMA
(307) 429-2029

Attachment